FATE Q4 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-26.4% YoY

Gross Profit

-$12M-842.4% margin

Operating Income

-$35M-2536.2% margin

Net Income

-$32M-2364.8% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-21.4%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$319M

Total Liabilities

$112M

Stockholders' Equity

$207M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-26.4%
Gross Profit	-$12M	$2M	-720.0%
Operating Income	-$35M	-$62M	+43.8%
Net Income	-$32M	-$52M	+37.9%